TABLE 1.
IMMUNOASSAYS FOR JCV: RATES VARY BETWEEN 33% TO 91%
| Country | N | Age (Yrs) | Population | Seropositive | Ref |
|---|---|---|---|---|---|
| Finland | 590 | 0-13 | Normal | 33% (VLPEIA) | 86 |
| 50 | >25 | 72% (VLPEIA) | |||
| UK | 2435 | 1-69 | Normal | 35% (HI) | 87 |
| 356 | 60-69 | 50% (HI) | |||
| USA | 1501 | >21 | Normal | 39% (VP1 EIA) | 88 |
| USA | 415 | 19-78 | Normal | 44% (VLPEIA) | 89 |
| 90 | 40-64 | Cancer | 52% (VLPEIA) | ||
| Belgium | 106 | 20-80 | Normal | 52% (VLPEIA) | 90 |
| 225 | 11-70 | Crohn's/GI | 76% (VLPEIA) | ||
| Switzerland | 400 | 20-59 | Normal | 58% (VLPEIA) | 91 |
| USA | 622 | 20-74 | Normal | 59% (VLPEIA) | 92 |
| 724 | 20-74 | Cancer | 49% (VLPEIA) | ||
| USA | 277 | >20 | Normal | 69% (HI) | 93 |
| Japan | 480 | All ages | Normal | 71% (HI) | 94 |
| Germany | 49 | 4-81 | Normal | 86% (VP1 EIA) | 95 |
| 36 | 17-55 | MS | 76% (VP1 EIA) | ||
| Portugal | 171 | 3-75 | Normal | 91% (VLPEIA) | 96 |
| 63 | 25-75 | HIV | 91% (VLPEIA) | ||
VLPEIA - Virus-Like Particle Enzyme Immunoassay
HI - Haemagglutination Inhibition
VP1 EIA - VP1 Enzyme Immunoassay